62
Views
0
CrossRef citations to date
0
Altmetric
Review

Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma

(Assistant Member) , , , &
 

Abstract

Introduction: Survival for patients with intraocular retinoblastoma (RB) is excellent. Over the past two decades, the focus of therapy has shifted to emphasize ocular salvage and vision preservation. The combination of chemoreduction and aggressive focal therapies has formed the new standard approach to most patients with advanced intraocular RB. However, seeding of the vitreous cavity continues to be the primary reason for treatment failure in these patients.

Areas covered: Local delivery methods, including periocular injections, intra-ophthalmic artery infusions, and intravitreal injections, have been developed in the hope of controlling disease in advanced cases. This review highlights the current approach to therapy for patients and discusses these new local delivery techniques and the discovery of novel therapeutics that may help to further improve ocular outcomes for patients with intraocular RB.

Expert opinion: Due to the rarity of this childhood disease, clinical efforts to improve ocular salvage and vision preservation must occur in parallel with translational research efforts that identify novel strategies for therapy of RB. A dedicated RB team provides guidance for a coordinated approach to address the key therapeutic, biologic, and long-term challenges in our patients.

Declaration of interest

This work has been supported in part by the American Lebanese Syrian Associated Charities (ALSAC) and National Institutes of Health grant numbers CA21765 and CA23099. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Notes

This box summarizes key points contained in the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.